Stock surges as company receives approval for innovative oral devices

  • Vivos Therapeutics shares more than doubled after FDA clearance
  • Stock rose 169% to $11.80 in early trading
  • Clearance applies to removable complete airway repositioning and/or expansion oral devices
  • Vivos Therapeutics is the first company to offer an alternative treatment to CPAP or surgical neurostimulation implants

Vivos Therapeutics experienced a significant surge in its stock price after receiving 510(k) clearance from the FDA for its oral appliances designed to treat severe obstructive sleep apnea. The stock rose by an impressive 169% to $11.80 in early trading, contributing to a 15% increase for the year. This clearance marks a significant milestone for the medical device and technology company, as it is the first to offer a clear alternative treatment to CPAP or surgical neurostimulation implants for patients with severe obstructive sleep apnea. The clearance applies to Vivos Therapeutics’ removable complete airway repositioning and/or expansion oral devices, providing patients with a new and innovative solution for their sleep apnea needs.

Factuality Level: 8
Factuality Justification: The article provides factual information about Vivos Therapeutics receiving 510(k) clearance from the FDA for treating severe obstructive sleep apnea using its oral appliances. It also mentions the increase in the company’s stock price and its claim of being the first company to offer an alternative treatment to CPAP or surgical neurostimulation implants. The article does not contain any obvious bias or misleading information.
Noise Level: 7
Noise Justification: The article provides some relevant information about Vivos Therapeutics receiving FDA clearance for treating sleep apnea. However, it lacks in-depth analysis, scientific rigor, and evidence to support its claims. It also does not explore the consequences of this clearance on patients or hold powerful people accountable. The article stays on topic but does not provide actionable insights or solutions. Overall, there is some noise and lack of substance in the article.
Financial Relevance: Yes
Financial Markets Impacted: Vivos Therapeutics
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article pertains to a financial topic as it discusses the significant increase in Vivos Therapeutics’ shares following the FDA clearance for their oral appliances. However, there is no mention of an extreme event or its impact.
Public Companies: Vivos Therapeutics (N/A), U.S. Food and Drug Administration (N/A)
Key People: Denny Jacob (N/A)

Reported publicly: www.marketwatch.com